SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Schrodinger, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.12+0.52 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
55.7%−3.0 pts over 5 years
Operating margin
-65.2%−8.9 pts over 5 years
Net margin
-40.4%−17.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +23.3% | +12.2% | +18.8% | – | |
| Gross profit | +8.0% | +12.2% | +17.6% | – | |
| Free cash flow | – | – | -2.6% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -9.2% | -26.3% | |
| Return on assets | – | -5.4% | -13.3% | |
| Current ratio | – | 9.33 | 2.75 | |
| Capex to revenue | – | 2.3% | 0.6% | |
| Diluted shares | – | 60M | 73M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Schrodinger generated $498.35M from operations and spent $37.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$498.35M
Used
$37.34M
Capital expenditure$37.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-40.4%
×Asset turnover0.33×
×Equity multiplier1.97×
=Return on equity, FY2025-26.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -40.4% | 0.33× | 1.97× | -26.3% |
| FY2024 | -90.2% | 0.26× | 1.68× | -38.6% |
| FY2023 | 18.8% | 0.29× | 1.50× | 8.2% |
| FY2022 | -82.4% | 0.25× | 1.44× | -29.7% |
| FY2021 | -72.8% | 0.18× | 1.27× | -17.0% |
| FY2020 | -22.6% | 0.24× | 1.70× | -9.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$103.27M
- Cash generatingOperating cash flow above zero$13.90M
- Return on assets improvedROA up on the prior year-23.3% → -12.5%
- Earnings backed by cashOperating cash flow above net income$13.90M vs -$103.27M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.31 → 2.75
- No dilutionShare count did not rise73M → 73M
- Gross margin improvedGross margin up on the prior year63.64% → 55.74%
- More efficientAsset turnover rose0.26 → 0.31